467 results about "Monocyte" patented technology

The invention discloses a bacterial strain for degrading aspartame, a bacterial-algae symbiotic system and application of the bacterial strain and the bacterial-algae symbiotic system, the bacterial strain is corn sphingomonas zeae NCU J1, and the preservation number of the bacterial strain is CCTCC (China Center for Type Culture Collection) NO: M 20251462. And an algal-bacterial symbiotic system is constructed by adopting an oriented symbiotic combination of the corn sphingomonas NCU J1 and the chlorella sp. The corn sphingomonas NCU J1 can metabolize an artificial sweetening agent aspartame and degradation products thereof, metabolism complementation can be achieved through an algal-bacterial symbiotic interface, and bacteria preferentially promote aspartame to be subjected to photohydrolysis to generate degradation products such as diketopiperazine derivatives. The microalgae synchronously start isomerism enzymatic reaction to convert degradation products such as diketopiperazine derivatives into low-toxicity products, the risk of secondary pollution is reduced by 40% or above compared with that of a traditional physical and chemical method, 150 mg / L aspartame can be efficiently degraded within 2 days, generation of derivatives of aspartame can be greatly reduced, secondary pollution is reduced, and the method is suitable for industrial production. And the method has a good application prospect in the aspect of rapidly treating aspartame-containing wastewater.

The invention provides an in-vitro skin blood vessel immune model as well as a preparation method and application thereof. THP-1 human monocyte leukemia cells are induced to be differentiated into M0 type macrophages, and then the M0 type macrophages are respectively induced into M1 type macrophages and / or M2 type macrophages; then co-culturing the M1 type and / or M2 type macrophages and vascular endothelial cells to form a vascular immune model; finally, the 3D skin model is placed on the blood vessel immune model, external stimulation is conducted, and the in-vitro skin blood vessel immune model is constructed. The in-vitro skin blood vessel immune model can be used for repairing skin barriers, inflammation pathways, blood vessel metabolism, the expression level of genes or proteins related to extracellular matrixes, vascular endothelial cells, the proliferation and migration ability of activated macrophages and the like. The seven feature dimensions of the physiological structure feature of the skin model are used for screening the to-be-tested sample and exploring the action mechanism, and the method has the characteristics of rapidness, multiple screening dimensions, high accuracy, low construction difficulty, low cost and high universality.

The invention belongs to the field of new application of medicines, and particularly relates to application of SIRT4-IN-1 in preparation of medicines for treating autoimmune diseases. It is found for the first time that SIRT4-IN-1 reduces the activation degree of immune response induced by HSV-1 virus infection by up-regulating acetylation modification of cGAS, inhibits abnormal activation of immune response in Trex1 deficient mouse cells and peripheral blood mononuclear cells of systemic lupus erythematosus patients, and improves abnormal activation of autoimmune response. The invention provides a new candidate drug for clinical treatment of systemic lupus erythematosus.

The invention provides a mononuclear cell for treating sepsis cardiomyopathy, and also relates to application of the mononuclear cell in preparation of drugs for improving sepsis and sepsis cardiomyopathy. The mononuclear cell provided by the invention can have a better targeted enrichment characteristic, so that the effective rate of treatment is improved, and meanwhile, toxic and side effects caused by non-specific distribution of drugs are reduced. Besides, the mononuclear cells are derived from the body of a healthy body, so that the mononuclear cells are more stable in metabolism, higher in absorption efficiency and more excellent in enrichment effect when acting on the body, and the technical problems that in-vivo half-life period of drugs is short and catabolism is easy in the prior art are solved.

The invention belongs to the technical field of food microorganisms, and particularly relates to an enterococcus lactis NSK220 strain, a microbial agent and application of the enterococcus lactis NSK220 strain. The invention provides the enterococcus faecium NSK220, the clearance rate of the enterococcus faecium NSK220 on DPPH is very high, the serum SOD enzyme activity can be improved by supplementing the strain NSK220 in diet, and it is indicated that the oxidation resistance of the strain NSK220 is high. Meanwhile, the enterococcus faecium NSK220 has relatively strong self-cohesion and surface hydrophobicity, which indicates that the strain has strong colonization ability and is beneficial to long-term play of probiotic functions in intestinal tracts; the strain NSK220 can also improve the feed intake and kidney function of animals, and is beneficial to the growth and body health of the animals. The enterococcus faecium NSK220 has an inhibition effect on escherichia coli, staphylococcus aureus, salmonella, pseudomonas aeruginosa and listeria monocytogenes.

The invention provides a composition for promoting differentiation of intestinal immune cells as well as a preparation method and application of the composition. According to the composition, 1, 3-dioleic acid-2-palmitic acid triglyceride and breast milk oligosaccharide are used in a combined manner, so that monocytes can be effectively promoted to differentiate into intestinal macrophages, and inflammation is reduced to a certain extent. After the monocytes are differentiated into the intestinal macrophages, the intestinal immune homeostasis and intestinal microbiota inflammatory response can be regulated, so that the mucosal immune homeostasis and intestinal epithelial cell barrier function are maintained. Therefore, the composition provided by the invention can improve the intestinal immune barrier by promoting the monocytes to differentiate into the intestinal macrophages, and provides a new thought for improving the early intestinal barrier of infants through nutritional supplement.

The invention relates to the technical field of microorganisms, in particular to a lactobacillus plantarum strain LM2 and application of the lactobacillus plantarum strain LM2. The strain has relatively high GABA (gamma-aminobutyric acid) production capacity and nitrite degradation capacity, has a bacteriostatic effect on intestinal pathogens such as staphylococcus aureus, salmonella enteritidis, listeria monocytogenes and campylobacter jejuni, has a good bacteriostatic function, also has good acid resistance and cholate resistance, and can be used for preparing a bacterial strain for treating intestinal diseases. The strain can well survive in artificial intestinal juice and artificial gastric juice; in order to increase the yield of GABA, the accelerant capable of remarkably promoting the growth of the strain LM2 is obtained by researching the accelerant, and the highest survival rate of the freeze-dried powder prepared by optimizing the accelerant and the freeze-dried powder can reach 99% or above, the nitrite degradation rate can reach 99% or above, the yield of GABA is increased to 3.0 g / L or above, and the freeze-dried powder is bacterial powder capable of being widely applied.

The invention relates to a lung cancer organoid and peripheral blood source immune cell co-culture model and a construction method thereof. Specifically, the invention provides a construction method of a macrophage and tumor organoid co-culture model for evaluating anti-tumor activity, monocytes of autologous or allogeneic peripheral blood of a patient are induced and differentiated into high-purity macrophages in vitro, and the high-purity macrophages and lung cancer tumor organoid are subjected to three-dimensional co-culture in matrigel; the model aims at highly reducing a core interaction network of tumor cells and macrophages in TME; the dynamic change of the polarization state of the macrophage is simulated and observed; the problem that an organ-like model is incomplete due to immune component deficiency or spatial positioning distortion of an existing model is effectively solved, an experimental platform closer to the physiological state is provided for tumor immune microenvironment research, and therefore development of the tumor immune treatment field is promoted.

The invention relates to the field of cell biology, and particularly relates to a preparation method of a pancreatic cancer-related antigen-loaded polypeptide, which is characterized in that factors such as GM-CSF, IL-4, IFN-gamma, TNF-alpha, IL-1beta, IL-6, PGE2, Poly I: C, R848 and the like are added to promote mononuclear cells to be activated into DC cells, pancreatic cancer PANC-1, MIA PaCa-2, BxPC-3, KP4 and SW1990HM antigens are loaded, and not only is DC cell maturation promoted, but also pancreatic cancer-related antigens are loaded. The positive rate of CD83 + CD86 of the DC cells cultured by the method is 94.16%, and the secretion amount of IL-12p70 in a cell supernatant is (645.38 + / -36.49) pg / mL. By adopting the culture method disclosed by the invention, the maturation rate of the DC cells can be improved while the DC cells are activated, so that the culture method for promoting the maturation and amplification of the DC cells loaded with the pancreatic cancer antigen is achieved.

The present application relates to the technical field of cell function detection, and particularly relates to a method for evaluating cell function of HL-60 in monocyte activation test. The method comprises the following steps: (1) preparing HL-60 cell suspension; (2) stimulating with pyrogen; (3) quantifying total protein; (4) detecting by Western blotting; and (5) evaluating cell function. The method is based on Western blotting technology, and combines statistical analysis to realize objective and quantitative determination of the core functional index of the ability of synthesizing IL-6 protein under pyrogen stimulation, can accurately identify cells with pyrogen response function defects, provides clear experimental reference for selection of HL-60 cell generations, can pre-screen qualified cells, reduces pyrogen detection deviation caused by unqualified cell function and improper generations from the source, and effectively improves the reliability and repeatability of pyrogen detection results.

The present invention relates to a ginseng peptide and a preparation method and application thereof, belonging to the field of biotechnology. The present invention provides a ginseng peptide, wherein the ginseng peptide comprises a characteristic peptide having an amino acid sequence of at least one of LY, MM, LR, AP, LAR, RLDFR, SALAFR, LLLLGH and LLLLLHG. The present invention obtains ginseng peptides by treating fermented ginseng residue, and identifies the characteristic peptides containing the amino acid sequences of LY, MM, LR, AP, LAR, RLDFR, SALAFR, LLLLGH and LLLLLHG in the ginseng peptides by HPLC-MS / MS. The present invention confirms through experiments that ginseng peptides and fermented ginseng hydrolysates containing ginseng peptides have excellent efficacy in inhibiting the differentiation of bone marrow mononuclear cells into osteoclasts, can improve hormone-induced osteoporosis, and can be applied to products for improving osteoporosis and its related symptoms.

Compositions and methods for treating inflammation associated with Farber disease in a subject in need thereof by administering to the subject a pharmaceutical composition comprising a recombinant human acid ceramidase in a therapeutically effective amount of about 0.1 mg / kg to about 50 mg / kg to inhibit inflammation and / or to inhibit or reduce pro-inflammatory potential of neutrophils and / or monocytes in the subject.

The present application relates to the technical field of bioinformatics, and particularly relates to a method for constructing a biological age prediction model based on DNA methylation. The method comprises the following steps: obtaining whole genome methylation sequencing data of a human peripheral blood sample; classifying cell subpopulations of the human peripheral blood sample, and performing single-cell RNA sequencing processing on each cell subpopulation to obtain single-cell sequencing data including lymphocytes, neutrophils and monocytes; performing tissue-specific analysis on CpG sites within a range of 2000 base pairs upstream and downstream of each cell subpopulation-specific transcription factor binding site according to the single-cell sequencing data and the whole genome methylation sequencing data to obtain candidate marker site data. The present application can provide strong support for early detection of accelerated aging, prediction of related disease risks and guidance of precision medicine.

Devices, systems, and methods can be used for the automated production of dendritic cells (DC) from dendritic cell progenitors, such as monocytes obtained from peripheral blood, and the automated generation of immunotherapeutic products from those dendritic cells, all within a closed system. The invention makes it possible to obtain sufficient quantities of a subject's own DC for use in preparing and characterizing vaccines, for activating and characterizing the activation state of the subject's immune response, and to aid in preventing and / or treating cancer or infectious disease.

The microorganism strain Pediococcus acidilactici TAK 589 CoccobEst is a new antimicrobial and antioxidant probiotic, CoccobEst inhibits the growth of the enteropathogens L. monocytogenes, E. coli, S. enteritidis, S. typhimurium, S. sonnei, S. aureus, E. faecalis and C. sakazakii, but does not inhibit lactobacilli of natural intestinal microbiota. The strain's antimicrobial properties are enhanced by periplasmic peptidoglycan hydrolases with proteolytic activity. CoccobEst is used as a zootechnieai feed additive to prevent bacterial infections in the gastrointestinal tract of farm animals and pets and to prevent and reduce diarrhea. CoccobEst has highly active antioxidant defense system, increasing the redox activity of glutathione and reducing oxidative stress in cells. Therefore, CoccobEst is used as a food supplement or functional food for humans to prevent bacterial infections of the gastrointestinal tract and to prevent and reduce oxidative stress. In addition, CoccobEst is used as a starter culture in fermentation of vegetables.

Disclosed in the present invention are an antibody capable of binding to human thymic stromal lymphopoietin (hTSLP), a preparation method therefor and an application thereof. The anti-hTSLP antibody of the present invention can specifically bind to a hTSLP receptor, has a good effect of inhibiting the secretion of TARC by PBMC, and can be applied to the treatment of TSLP-related diseases, such as immune-mediated inflammatory diseases.

The invention provides an aerosol-type face pack cosmetic that, when dispensed, forms a flexible, easy-to-use, and low-irritation resin foam that easily adheres to the face, such as around the eyes and nose. It also allows the fermented liquid contained in the resin foam to easily seep out, making it easy to apply the fermented liquid to the face and less likely to cause tightness. [Solution] An aerosol pack cosmetic comprising a beauty serum and dimethyl ether, wherein the beauty serum comprises at least one fermentation solution selected from Saccharomyces / Anzange ferment filtrate, Saccharomyces / Human (fibroblast / mononuclear cell) induced pluripotent cell culture conditioned medium ferment filtrate, Galactomyces / Eryngium multiflorum callus culture ferment filtrate, and a resin.

This document provides a method for generating human heart organoids (hHO) with integrated macrophages (MPs), the method comprising adding monocytes to a first culture medium containing hHOs, wherein the hHOs have been differentiated for at least 5 days, and agitating the hHOs, monocytes, and the first culture medium or fresh culture medium to generate hHOs with integrated MPs. hHOs with integrated MPs prepared by the disclosed method are also provided.

The invention relates to an ROS (reactive oxygen species) response type nano prodrug based on dynamic differentiation of monocytes as well as a preparation method and application of the ROS response type nano prodrug. According to the preparation method, citral and captopril react to form a captopril-citral prodrug molecule (Citopril) through a thioketal bond, and then the prodrug molecule and polyethylene glycol lipid are self-assembled in a water-containing solvent, so that the ROS response type nano prodrug (Citopp-NM) capable of being efficiently taken in by blood monocytes is prepared. According to the nano prodrug, dynamic differentiation of mononuclear cells is fully utilized, a nano drug delivery strategy of the mononuclear cells and the ROS responsive activation characteristic of the nano prodrug are combined, more efficient enrichment of the nano prodrug in AS plaques is achieved, activation of the nano prodrug is controlled through differentiation of the mononuclear cells, and the nano prodrug has a good application prospect. Therefore, distribution and activation of drugs in normal tissues can be reduced, the drug effect is improved, and toxic and side effects of the drugs are reduced.

The present disclosure provides methods and kits for determining antigen-specific T cell responses in a subject based on the use of a whole blood sample rather than isolated, enriched, and / or extracted peripheral blood mononuclear cells. The use of a whole blood sample to measure antigen-specific T cell responses in a subject streamlines the method by reducing sample preparation and consumption. These methods for determining antigen-specific T cell responses in a subject include contacting a whole blood sample from the subject with at least one antigen to form a mixture, contacting the whole blood sample with at least one staining reagent, and analyzing the mixture for antigen-specific T cells.

The present invention relates to a method of producing macrophages. The macrophages are produced from monocytes harvested from a subject by incubating said monocytes in a medium comprising a Colony Stimulating Factor 1 Receptor (CSF-1R) agonist. Before monocytes are harvested, the subject is treated with G-CSF. The macrophages produced by the method are capable of being polarised to a pro-restorative, anti-inflammatory and / or anti-fibrotic phenotype. The invention also relates to methods of treating inflammatory diseases comprising administering the macrophages produced by the method to a subject.

The invention belongs to the technical field of microbiological detection, and particularly relates to a rapid detection method for listeria monocytogenes RAA-CRISPR / Cas12a and application of the rapid detection method for the listeria monocytogenes RAA-CRISPR / Cas12a. According to the present invention, based on the combination of the recombinase polymerase amplification (RAA) and the CRISPR-Cas12a system, the ultra-sensitive and rapid detection of the Listeria monocytogenes is achieved through the constant temperature nucleic acid amplification and the specific gene recognition; the sensitivity reaches 3.6 CFU / mL (bacterial liquid) and 3.78 copies / L (genome DNA); the detection time is shortened to 26 minutes, and the method can be applied to rapid detection of various environmental samples.

An apparatus and method for T-cell separation, activation, transduction and expansion. Three-dimensional (3D) bioreactors may be employed that include antibody coatings. Such 3D bioreactors can be employed for T-cell separation from peripheral blood mononuclear cells including attachment of T-cells to the 3D bioreactor surface for activation and transduction by lentivirus vectors to produce CAR T-cells. The CAR T-cells can then be expanded in a separate downstream bioreactor therein providing a scalable automated system.

The present disclosure describes PLPC-DB, an ultrapure phospholipoproteomic composition consisting of essential phospholipids, bioactive proteins, and intercellular regulatory factors, derived from the supernatant of peripheral blood mononuclear cells (PBMCs). This composition achieves a purity level exceeding 99% through a patented purification process that integrates high-speed advanced centrifugation and selective ultrafiltration, ensuring the structural stability and functional integrity of its bioactive components. PLPC-DB is optimized for advanced research and diagnostic applications, providing reproducibility, consistency, and safety across multicenter studies. The essential biomolecular components of PLPC-DB include phosphatidylcholine and phosphatidylserine, which contribute to membrane stability and intracellular signaling, while cell communication peptides enhance intercellular signaling, homeostatic regulation, and biochemical coordination. Structural and regulatory lipids support cell membrane biogenesis and functional stability, whereas adhesion and signaling proteins mediate cell-cell interactions and immune response coordination. Additionally, bioactive regulatory factors modulate immune and inflammatory responses, contributing to tissue regeneration and metabolic homeostasis.

The present disclosure belongs to the field of biotechnology, and specifically relates to a preparation method for an adenovirus p53 (Ad-p53)-loaded dendritic cell (DC) vaccine. The present disclosure includes steps of peripheral blood collection and peripheral blood mononuclear cell (PBMC) separation, PBMC sorting, DC activation, Ad-P53-transfected DC and DC vaccine preparation. P53 can be expressed on a surface of DC as a tumor-associated antigen (TAA) through DC purification, specific multiplicity of infection (MOI) and infection modes, and the Ad-P53-transfected DC has obvious antigen presentation effect, which can be used as a vaccine to activate T cells to kill tumors.

The invention discloses an osteoclast culture method as well as a culture medium and application thereof, the culture method is based on primary monocyte extraction, inoculation is performed according to a specific density, then quantitative M-CSF is added, and culture is performed overnight; on the second day, when the cell confluence degree of the mononuclear bone marrow hematopoietic stem cells is 5-30%, supplementing quantitative RANKL into each hole, continuously culturing for 2-4 days, then changing the solution, and obtaining mature osteoclasts on the sixth-seventh day. According to the invention, the optimization relationship among the cell activity, the cell density and the culture medium in the primary culture process of the osteoclast is deeply studied, and from the perspective of cost reduction and efficiency improvement, the use cost of cell factors is remarkably reduced, the number of times of liquid change is reduced, and the traditional culture time of 10-12 days (calculated from cell extraction) is shortened to 6-7 days. The average diameter of the mature osteoclast cultured by the method is larger, the number of fused cell nucleuses is larger, the space proportion of the mature osteoclast is not less than 80%, and the cell quality is obviously higher than that in the prior art.

The invention discloses an application of a circRNA (Ribonucleic Acid) marker in preparation of a reagent for diagnosing rheumatoid arthritis, the circRNA marker is hsacircRNA001715, and the expression of the hsacircRNA001715 in peripheral blood mononuclear cells of a cold-dampness arthralgia type rheumatoid arthritis patient (active stage and inactive stage) is obviously up-regulated compared with that of a healthy control person; in addition, the hsacircRNA001715 can be used for up-regulating the expression of a peripheral blood mononuclear cell NLRP3 of a patient with the cold-dampness arthralgia type RA in the active period through an hsacircRNA001715 / miR-1249-5p axis and promoting an inflammatory reaction; the invention further discloses a kit for rheumatoid arthritis diagnosis, the kit can be rapidly used for early diagnosis of rheumatoid arthritis by detecting the expression level of hsacircRNA001715, operation is easy and convenient, accuracy is high, and a new strategy can be provided for clinical diagnosis of rheumatoid arthritis.

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

Provided are: an adeno-associated virus (AAV) vector, the AAV vector comprising a cytokine gene, and the cytokine being selected from any one or two or more of the following: IL3, GM-CSF, IL6, APRIL, and BAFF; an AAV vector combination comprising any two or three or more of said AAV vectors; and a method for constructing an acute myeloid leukemia xenograft non-human animal and a method for constructing a multiple myeloma xenograft non-human animal. In addition, further provided is another adeno-associated virus (AAV) vector, the AAV vector comprising a cytokine gene, and the cytokine being selected from any one or two or more of the following: IL2, IL3, IL6, IL15, THPO, SCF, and GM-CSF; further provided is an AAV vector combination comprising any two or three or more of said AAV vectors; and further provided is the use of the AAV vector and AAV vector combination in the construction of a humanized immune system non-human animal, as well as a method for constructing a humanized immune system non-human animal and a method for promoting the differentiation of human hematopoietic stem cells into CD14+ monocytes and CD66b+ granulocytes.

Methods and compositions relating to the treatment of degenerative disc disease are provided.SOLUTION: In some embodiments, cannabidiol is utilized to enhance the therapeutic and / or regenerative activity of fibroblasts. In other embodiments, cannabidiol is utilized to augment the reparative effects of other regenerative cells, including monocytes, mesenchymal stem cells, and / or hematopoietic stem cells. In some embodiments, cannabidiol is utilized in the culture media of regenerative cells prior to administration of said cells.SELECTED DRAWING: Figure 1